Home Cart Sign in  
Chemical Structure| 148707-39-5 Chemical Structure| 148707-39-5

Structure of EGCG Octaacetate
CAS No.: 148707-39-5

Chemical Structure| 148707-39-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

EGCG Octaacetate is a precursor of epigallocatechin gallate with anti-inflammatory and antibacterial properties, combating inflammation and cancer by regulating the PI3K/Akt/NFκB signaling pathway.

Synonyms: Peracetylated (-)-epigallocatechin-3-gallate; AcEGCG

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of EGCG Octaacetate

CAS No. :148707-39-5
Formula : C38H34O19
M.W : 794.67
SMILES Code : O=C(O[C@H]1[C@@H](C2=CC(OC(C)=O)=C(OC(C)=O)C(OC(C)=O)=C2)OC3=CC(OC(C)=O)=CC(OC(C)=O)=C3C1)C4=CC(OC(C)=O)=C(OC(C)=O)C(OC(C)=O)=C4
Synonyms :
Peracetylated (-)-epigallocatechin-3-gallate; AcEGCG
MDL No. :MFCD11983067

Safety of EGCG Octaacetate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MRL/lpr mouse mesangial cells 50 μM 1 h EGCG significantly inhibited iNOS protein expression and supernatant NO levels, and reduced IL-6 production. PMC4001894
Naïve CD4+ T cells 10 μM 72 h To evaluate the effect of EGCG on the proliferation of naïve CD4+ T cells. EGCG treatment inhibited the division of naïve CD4+ T cells stimulated with anti-CD3/CD28 antibodies, increasing the proportion of cells arrested in the G0/G1 phase by 8.6% and reducing DNA synthesis activity in the S phase by 51%. PMC10333431
Human umbilical vein endothelial cells (HUVECS) 100 µM 60 min EGCG increased NO levels and restored NO levels in PE plasma-treated cells via the PI3K/Akt/eNOS pathway. PMC10886151
Primary human hepatocytes (PHHs) 12.5, 25, and 50 μM 24 h EGCG significantly downregulated HMGB1 secretion and cytoplasmic HMGB1 levels in HBV-infected PHHs PMC10140519
HepAD38 cells 12.5, 25, and 50 μM 24 h EGCG significantly downregulated HMGB1 secretion in HBV-replicating hepatoma cells and activated autophagic degradation of cytoplasmic HMGB1 PMC10140519
Human bronchial epithelial (HBE) cells 5, 10, 20, 40 µM 24, 48, 72 h EGCG inhibited CSE-induced benzopyrene-DNA adduct formation and modulated miRNA expression profiles. PMC8559702
OGD/R-treated HL-1 cells 40 μM 3 h EGCG treatment promoted the viability of OGD/R cells and suppressed LDH levels, with 40 μM EGCG showing the best effects. PMC10698898
HL-1 cells 0, 5, 10, 20, 40, 80, 100 μM 3 h To evaluate the effect of EGCG on HL-1 cell viability, results showed that EGCG treatment did not exert significant toxicity on HL-1 cells. PMC10698898

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats Natural aging rats with cognitive impairments Intragastric administration 100 mg/kg Once daily for 4 weeks EGCG significantly ameliorated learning and memory impairments in natural aging rats with CI and decreased Aβ1–42 plaque formation in their brains PMC6888860
Sprague-Dawley rats Lithium-pilocarpine-induced status epilepticus model Intracerebroventricular injection 50 μM Continuous administration EGCG attenuates CA1 neuronal death induced by status epilepticus by regulating GPx1, NF-κB S536 phosphorylation, and mitochondrial dynamics PMC10136286
Mice Recombinant cccDNA (rcccDNA) chronic HBV mouse model Intraperitoneal injection 25 mg/kg Daily for 42 consecutive days EGCG treatment significantly alleviated HBV-induced liver injury and fibrosis by autophagic degradation of HMGB1 in hepatocytes and suppression of macrophage NLRP3 inflammasome activation PMC10140519
Sprague Dawley rats Cigarette smoke inhalation-induced precancerous bronchial epithelial lesions Drinking water 0.3% EGCG,in drinking water Daily for 16 weeks EGCG significantly reduced cigarette smoke-induced benzopyrene-DNA adduct formation and the development of precancerous bronchial epithelial lesions. PMC8559702
C57BL mice Myocardial infarction model Oral gavage 50 mg/kg Once daily for 4 weeks EGCG treatment improved cardiac function in MI mice, reduced myocardial infarction size, and inhibited AIM2 inflammasome-mediated pyroptosis. PMC10698898
Sprague-Dawley rats Cardiac arrest/cardiopulmonary resuscitation (CA/CPR) model Intravenous injection 3 mg/kg and 9 mg/kg Single dose, observed for 24 hours EGCG dose-dependently alleviated the IRI after CA/CPR, inhibited ERK activity and restored mitochondrial function, as indicated by improved NDS, reduced ROS level, decreased mPTP opening, elevated ATP content, increased ATPase expression and downregulated cleaved-caspase 3 level. PMC6689542

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.26mL

0.25mL

0.13mL

6.29mL

1.26mL

0.63mL

12.58mL

2.52mL

1.26mL

 

Historical Records

Categories